DCC4938 |
Stat5b-in-6a |
Highly Potent and Selective Inhibitor of the Transcription Factor STAT5b |
|
DCC4939 |
Stemazole |
Novel human stem/progenitor cells proliferation activator, promoting survival and preserving stemness in human embryonic stem cells |
|
DCC4940 |
Sterigmatocystin |
Natural inducer of G1 arrest in primary human esophageal epithelial cells but G2 arrest in immortalized cells |
|
DCC4941 |
Stf-038533 |
Novel inhibitor of expression from canonical CREB response element-containing promoters |
|
DCC4942 |
Stg -001 |
Novel RBP4 antagonist for treatment of Stargardt disease |
|
DCC4943 |
Stictic Acid |
Natural anti-feline infectious peritonitis virus (FIPV) agent, specifically targeting the 3CLpro of FIPV and inhibiting its replication |
|
DCC4944 |
Sting Agonist 11 |
Novel non-nucleotide STING agonist, demonstrating antitumor activity when dosed intratumorally in a syngeneic mouse model |
|
DCC4945 |
Sting Inhibitor C-171 |
Novel covalent antagonist of hsSTING |
|
DCC4946 |
Stk-15 |
Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
|
DCC4947 |
Stk-22 |
Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
|
DCC4948 |
Stk295900 |
Dual inhibitor of topoisomerase 1 and 2, inducing G(2) arrest in the absence of DNA damage. Inhibitor of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay |
|
DCC4949 |
Stk508411 |
Novel inhibitor of the heterogeneous ribonuclear protein A18 (hnRNP A18) |
|
DCC4950 |
Stk630921 |
Novel blocker of IL-17A binding to the IL-17A receptor (IL-17RA) |
|
DCC4951 |
Stk683963 |
Novel activator of cellular ATG4B activity |
|
DCC4952 |
Stock1n-65837 |
Potent natural modulator of human Toll-like receptor 7 (TLR7) |
|
DCC4953 |
Streptolidine |
Metablite of the Streptomyces antibiotics streptothricin and streptolin |
|
DCC4954 |
Streptozocin |
Antibiotic, being used as an antineoplastic agent and to induce diabetes in experimental animals |
|
DCC4955 |
Sts-e412 |
The first nonpeptidyl, selective activator of the tissue-protective EPOR/CD131 receptor |
|
DCC4956 |
Sts-e424 |
Novel agonist of the tissue-protective erythropoietin (EPO) receptor, increasing FXN expression and EPOR phosphorylation |
|
DCC4957 |
Stx-2622 |
Inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs) |
|
DCC4958 |
Stx2845 |
Novel Nonsteroidal Inhibitor of Carbonic Anhydrase IX |
|
DCC4959 |
Su0383 |
Novel dual Inhibitor of repair enzymes 8-oxoguanine DNA glycosylase (OGG1) and human MutT Homolog 1 (NUDT1 or MTH1), increasing sensitivity of tumor cells to oxidative stress |
|
DCC4960 |
Su11272 |
Novel potent c-MET inhibitor |
|
DCC4961 |
Su11606 |
Potent c-MET inhibitor |
|
DCC4962 |
Su11652 |
Sunitinib analog, acting as a potential inhibitor for nucleoside diphosphate kinase (NDK) from Leishmania major (LmNDK) |
|
DCC4963 |
Su-200 |
Agonist of TRPV1 |
|
DCC4964 |
Su9518 |
Novel potent and selective inhibitor of the cellular PDGF receptor kinase and PDGF receptor-induced cell proliferation |
|
DCC4965 |
Subglutinol A |
Natural immunosuppressive agent, effectively blocking T cell proliferation and survival while profoundly inhibiting pro-inflammatory IFNγ and IL-17 production by fully differentiated effector Th1 and Th17 cells, also acting as an estrogen receptor antagon |
|
DCC4966 |
Suc-leu-leu-val-tyr-amc |
Fluorescent substrate which can be hydrolyzed by the proteasome to release free AMC and the fluorescence of which is proportional to the proteasome activity |
|
DCC4967 |
Sucnr1-in-20
Featured
|
SUCNR1-IN-2 (Statement 35) is a succinate/succinate receptor 1 inhibitor for the study of neurodegenerative diseases such as neuroinflammation. |
|